NewLimit, co-founded by Coinbase CEO Brian Armstrong, raises $435M at a $3.1B valuation for its epigenetic reprogramming approach to reversing aging.

Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.

NewLimit said Tuesday it has raised a $435 million Series C round at a $3.1 billion post-money valuation.